---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-230659"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2023-09-07T23:59:59+00:00"
generated_at: "2026-06-10T22:46:45.784749+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics president Tom Dubensky resigns; CEO Stephen Brady to assume president role

## Summary
- Tom Dubensky resigned as president and board member effective Sep 2, 2023; will transition to advisor role on Sep 15, 2023.
- Resignation not due to any disagreement with Tempest on operations, policies, or practices.
- CEO Stephen Brady will be appointed as president and CEO effective Sep 15, 2023; his responsibilities unchanged.
- Dubensky expected to enter consulting agreement: $8,000 retainer for initial period (Sep 15–Oct 15), then $500/hour for services.
- Consulting period expected until at least Dec 15, 2023.

## SEC filing metadata
- accession: 0001193125-23-230659
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2023-09-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/0001193125-23-230659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/d532461d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-230659
- JSON: https://secwatch.observer/filing/0001193125-23-230659.json
- Plain text: https://secwatch.observer/filing/0001193125-23-230659.txt

## Key facts
- Executive change
  Stephen Brady was appointed as President and Chief Executive Officer at Tempest Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Board will appoint Stephen Brady, the Company’s chief executive officer, as president and chief executive officer effective as of the Separation Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/0001193125-23-230659-index.htm
- Executive change
  Tom Dubensky resigned as President and member of the Board of Directors at Tempest Therapeutics, Inc..
  - Action: resigned
  - Role: President and member of the Board of Directors
  source text: On September 2, 2023, Tom Dubensky, Ph.D. resigned from his role as president and member of the Board of Directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/0001193125-23-230659-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.